The Effect of Pollen Season on Subcutaneous Allergen Immunotherapy Reactions
Status unconfirmed · Phase 1/Phase 2
Conditions studied: Allergic Rhinitis, Asthma, Allergic Conjunctivitis
In brief
Subcutaneous allergen immunotherapy (SCIT) is a widely used and effective treatment modality for allergic rhinoconjunctivitis and asthma. SCIT starts with a build-up phase during which a patient receives frequent, escalating doses of the allergens they are allergic to until they reach a predetermined maintenance dose. This is followed by a maintenance phase during which the allergen dose is kept constant and administered at greater intervals. Maximum clinical improvement is generally not seen until a patient is in the maintenance phase. Anecdotal evidence of possible reactions to SCIT administered during a patient's pollen season has led to dosage freezes during a patient's pollen season which extends the length of the build-up phase by many months. Prolonging the buildup phase increases the time required to obtain maximal benefit from SCIT, and at the same time, can decrease patient compliance with therapy due to the prolonged period of time when frequent injections are required. The aims of this study are to determine if adverse reactions to pollen SCIT are increased if doses are increased during pollen season.
Key facts
- Study ID
- NCT01878929
- Run by
- University Hospitals Cleveland Medical Center
- People needed
- 245
- Starts
- 2013-04-01
- Expected to finish
- 2014-04-01
- Last updated by the study team
- 2013-06-17
Who can join
Age: 5 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- include individuals ages 5 and greater at Allergy/Immunology Associates, Inc., who are receiving build-up SCIT to tree, grass, and/or weed pollens for allergic rhinitis, allergic conjunctivitis, and/or asthma
You may not qualify if…
- are in maintenance phase of SCIT
- are on beta-blockers
- have a forced expiratory volume in 1 second (FEV1) of less than 70% of predicted
- have a history of anaphylaxis with previous SCIT to aeroallergens (as defined by the requirement of intramuscular or subcutaneous epinephrine for treatment of a SCIT-induced reaction)
- have any uncontrolled cardiac or pulmonary disease as determined by their treating allergist/immunologist
- are pregnant, due to risk of harm to fetus if anaphylaxis occurs.
Where it is running
- Allergy/Immunology Associates Inc. — South Euclid, Ohio, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.